Hims & Hers Health missade intäktsprognosen under det första kvartalet till följd av marginalpress.
Företaget rör sig bort från egenberedda GLP-1-läkemedel mot varumärkessamarbeten med Novo Nordisk och Eli Lilly. Denna förändring förväntas påverka marginalerna på kort sikt samtidigt som de juridiska riskerna kopplade till egenberedning minskar.
Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
Rapporterad av AI
ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
L’Oréal Group posted a 7.6% like-for-like revenue increase to €12.2 billion in the first quarter of fiscal 2026, exceeding analyst expectations. The results marked an acceleration from the previous quarter. CEO Nicolas Hieronimus credited innovation and e-commerce strength for global market share gains.
Rapporterad av AI
Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.